GPT and non-small cell lung carcinoma: In comparison, a recent retrospective cohort study found that only 7 out of 181 patients with advanced NSCLC (3.9%) receiving immune checkpoint blockade monotherapy experienced grade ≥3 ALT or AST increase.14